Pharmaceuticals

FDA Approves Ascendis Pharma’s Yorbipath as First Treatment for Adults with Hypoparathyroidism

bexib
By bexib 0 Min Read

Yorbipath is designed to deliver parathyroid hormone over a 24-hour period to patients with hypoparathyroidism.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article SEO tools that analyze HTML headings
Next Article Remain bullish on dollar, sell on EUR/USD rise – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Curling Club – Now open at 2 sites
Hospitality & Tourism
Calculated risk: Friday: Retail sales, industrial production
Economy
Renaissance vs. ASNOA Insurance – Which agent network is best for you?
Insurance
Only 40% of financial institutions are satisfied with cloud investing
Banking